Clinical Trial

Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis Circulating in Central Africa Region

Study acronym: MESTCAR
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 12, 2025 (before its estimated November 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge in Central Africa. Understanding the molecular epidemiology and genotypic characteristics of MDR-TB strains is crucial for effective control measures. This is highlighted by the emergence of mutations encoding resistance to bed aquiline and quinolones which may impact the roll out of the newly recommended Bedaquiline, Pretomanid, Linezolid and Moxifloxacin (BPaLM) regimens. It is also worth noting that there is increasing evidence of the significance of TB lineage in the outcome of infection, the approach in the study will provide both information on chains of transmission and lineage.
Trial Details
NCT Number NCT07017803
Lead Sponsor Centre de Recherche Médicale de Lambaréné
Collaborators: Fondation Congolaise pour la Recherche Médicale, Centre Pasteur du Cameroun, GlaxoSmithKline
Conditions Tuberculosis, Multi Drug Resistant, Strains, Molecular Epidemiology, Multi Drug Resistant Tuberculosis, Central Africa
Enrollment 460 participants
Start Date 2025-07-01
Primary Completion 2025-11-30 (estimated)
Study Completion 2026-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-12